Spots Global Cancer Trial Database for apatinib
Every month we try and update this database with for apatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | NCT03201146 | Lung Cancer Non Small Cell ... Combination Che... Apatinib | Apatinib AP or AC Apatinib 250mg Apatinib 500mg Apatinib 750mg | 18 Years - 70 Years | West China Hospital | |
| Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma | NCT04724226 | Hepatocellular ... | Camrelizumab; A... | 18 Years - 70 Years | Sun Yat-sen University | |
| Study of Apatinib as an Inhibitor of Tumor Angiogenesis | NCT00633490 | Tumor | apatinib | 18 Years - 70 Years | Fudan University | |
| Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma | NCT03359018 | Progression-fre... Overall Surviva... Clinical Benefi... Toxicity | Apatinib SHR-1210 | 11 Years - | Peking University People's Hospital | |
| A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma | NCT03071042 | Metastatic Gast... | Apatinib Docetaxel | 18 Years - | Sir Run Run Shaw Hospital | |
| Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer | NCT02867956 | Ovarian Cancer | Apatinib Etoposide | 18 Years - 70 Years | Sun Yat-sen University | |
| Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | NCT06161272 | Ovarian Cancer High Grade Sero... Primary Periton... Fallopian Tube ... | Fluzoparib Fluzoparib+Apat... | 18 Years - 75 Years | Guangxi Medical University | |
| Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy | NCT03742193 | Osteosarcoma Pulmonary Metas... Apatinib | Apatinib GD regimen | 10 Years - 50 Years | Ruijin Hospital | |
| A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations | NCT03634059 | NSCLC | Apatinib | 18 Years - 75 Years | Hebei Medical University Fourth Hospital | |
| APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC | NCT03164694 | Lung Cancer | Apatinib Pemetrexed Carboplatin | 18 Years - 75 Years | Sun Yat-sen University | |
| Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma | NCT03376958 | Relapsed and Re... Diffuse Large B... | Apatinib | 14 Years - 70 Years | Zhengzhou University | |
| SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer | NCT03603756 | Esophageal Squa... | SHR-1210 Apatinib Irinotecan Inje... Paclitaxel lipo... Nedaplatin | 18 Years - 70 Years | ChineseAMS | |
| Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer | NCT03219593 | Gastric Cancer Apatinib Biomarker | Apatinib mesyla... | 65 Years - | First Affiliated Hospital Bengbu Medical College | |
| Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer | NCT04201990 | Lung Cancer | Camrelizumab an... | 18 Years - 75 Years | Guangzhou Institute of Respiratory Disease | |
| Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma | NCT03398122 | Hepatocellular ... | TACE Apatinib | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer | NCT03129698 | Apatinib in Mai... | Apatinib | 18 Years - 75 Years | Peking Union Medical College | |
| Apatinib for Inoperable Advanced Chondrosarcoma | NCT04260113 | Efficacy Toxicity, Drug | Apatinib Mesyla... | - | Peking University People's Hospital | |
| A Study of Apatinib Treatment in for Advanced Ovarian Cancer | NCT03393507 | Ovarian Cancer Chemotherapeuti... | Apatinib Taxus + platinu... | 18 Years - 75 Years | The People's Hospital of Leshan | |
| Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC) | NCT03416231 | NSCLC | Apatinib Docetaxel | 18 Years - | Affiliated Hospital of North Sichuan Medical College | |
| Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell | NCT05049681 | Esophageal Canc... | Camrelizumab Apatinib | 18 Years - 75 Years | The First Affiliated Hospital of Zhengzhou University | |
| Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | NCT04548271 | Nasopharyngeal ... | Camrelizumab Apatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC | NCT03389256 | Lung Diseases Neoplasms Respiratory Tra... Thoracic Neopla... Non-Small-Cell ... | Apatinib EGFR-TKI | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery | NCT03722875 | Hepatocellular ... | SHR-1210 apatinib | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC) | NCT03046979 | Hepatocellular ... | Apatinib | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer | NCT01512745 | Advanced or Met... | apatinib placebo | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas | NCT05142865 | Advanced or Met... | Camrelizumab Etoposide Carboplatin Cisplatin Apatinib | 18 Years - 75 Years | Huazhong University of Science and Technology | |
| Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy | NCT02711007 | Osteosarcoma Metastasis | apatinib | 16 Years - | Peking University People's Hospital | |
| Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer | NCT04067986 | Colorectal Canc... | Camrelizumab Apatinib | 18 Years - 75 Years | Zhongshan Hospital Xiamen University | |
| A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma | NCT03609489 | Biliary Carcino... | Capecitabine Apatinib | 18 Years - 75 Years | First Affiliated Hospital of Guangxi Medical University | |
| Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors | NCT03660761 | Efficacy and Sa... | apatinib temodar | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial | NCT05198609 | Hepatocellular ... | FOLFOX-HAIC Camrelizumab Apatinib | 18 Years - | Sun Yat-sen University | |
| Apatinib Treatment for Advanced Esophagus Cancer | NCT03170310 | Advanced Esopha... | Apatinib | 18 Years - 75 Years | Henan Cancer Hospital | |
| A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer | NCT02409199 | Gastric Carcino... | Docetaxel apatinib | 18 Years - | Shanghai Zhongshan Hospital | |
| A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | NCT04191889 | C-staged Hepato... | Hepatic Arteria... | 18 Years - 70 Years | Sun Yat-sen University | |
| Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC | NCT04682249 | ICC | Systemic Chemot... Sintilimab Apatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| The Real World Study of Apatinib for Gastric Cancer Treatment in Anhui Province | NCT03333967 | Gastric Cancer | 18 Years - | The First Affiliated Hospital of Anhui Medical University | ||
| Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer | NCT02998242 | Quality of Life | Apatinib SBRT to symptom... | 18 Years - 90 Years | Sichuan Provincial People's Hospital | |
| An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer | NCT02668380 | Metastatic Gast... | 18 Years - | Peking Union Medical College Hospital | ||
| Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | NCT04350190 | Nasopharyngeal ... | Apatinib mesyla... PD-1 | 18 Years - 70 Years | Guilin Medical University, China | |
| Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer | NCT04612894 | Thyroid Cancer | Camrelizumab an... surgery core needle bio... | 14 Years - | Fudan University | |
| A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | NCT03251443 | Intrahepatic Ch... Second-line Tre... | Apatinib | 18 Years - | Peking Union Medical College Hospital | |
| Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer | NCT05853172 | Gastric Cancer | AK104 Apatinib Paclitaxel S-1 | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer | NCT03298074 | Ovarian Cancer | Apatinib Etoposide | 18 Years - | Guangxi Medical University | |
| Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients | NCT02829385 | Colorectal Neop... | Apatinib and XE... | 18 Years - 75 Years | LanZhou University | |
| Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma | NCT03612219 | Nasopharyngeal ... | Apatinib mesyla... Intensity-modul... Cisplatin | 18 Years - 70 Years | Guilin Medical University, China | |
| An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric | NCT03285906 | Esophagus Cance... Esophageal Gast... Esophagus Cance... | Apatinib | 18 Years - 80 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer | NCT04642664 | Biliary Tract C... Cholangiocarcin... Biomarker Hepatobiliary N... | Apatinib plus C... | 18 Years - | Peking Union Medical College Hospital | |
| SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery | NCT03722875 | Hepatocellular ... | SHR-1210 apatinib | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations | NCT02824458 | EGFR Tyrosine K... | Apatinib Gefitinib Placebo | 18 Years - 70 Years | Sun Yat-sen University | |
| Apatinib for Metastatic Esophageal Cancer. | NCT02544737 | Esophageal Canc... Metastatic Esop... Apatinib | Apatinib | 19 Years - | Hangzhou Cancer Hospital | |
| Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma | NCT03567135 | Glioblastoma | Apatinib Temozolomide（TM... | 18 Years - 70 Years | Fuzhou General Hospital | |
| Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen | NCT03792503 | Advanced Non-sq... | Apatinib Pemetrexed | 18 Years - | Xinqiao Hospital of Chongqing | |
| A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer | NCT01270386 | Non-Small-Cell ... | apatinib placebo | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer | NCT03229096 | Chemotherapy Ef... Chemotherapeuti... Gastric Cancer | Apatinib plus X... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | NCT05447702 | Triple Negative... | Camrelizumab Apatinib Nab-paclitaxel Epirubicin Cyclophosphamid... | 18 Years - 75 Years | West China Hospital | |
| Study of Apatinib and MASCT in Patients With Advanced Solid Tumors | NCT02844881 | Advanced Solid ... Excluding T Cel... | Apatinib MASCT | 18 Years - 80 Years | The First People's Hospital of Lianyungang | |
| MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma | NCT04074564 | Sarcoma | MASCT-I, Camrel... | 14 Years - 70 Years | HRYZ Biotech Co. | |
| Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC | NCT03411967 | Lung Cancer | Apatinib Docetaxel | 18 Years - | Zigong No.1 Peoples Hospital | |
| Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma | NCT05924997 | Advanced Hepato... | adebrelimab, ca... | 18 Years - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma | NCT04824352 | Effect of Drug Toxicity, Drug | apatinib | 12 Years - 70 Years | Peking University People's Hospital | |
| Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer | NCT03050411 | Nonsmall Cell L... | Apatinib Mesyla... EGFR-TKIs (Erlo... | 18 Years - 75 Years | Peking University Third Hospital | |
| A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy | NCT02776527 | Gastric Cancer | Apatinib Mesyla... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation | NCT03758677 | Non Small Cell ... | Apatinib | 18 Years - 75 Years | The First Hospital of Jilin University | |
| Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma | NCT06339619 | Locally Advance... | Adebrelimab Apatinib Tegafur | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer | NCT03377842 | Colorectal Canc... Neoadjuvant The... | FOLFOX regimen apatinib and FO... | 18 Years - | Sichuan Provincial People's Hospital | |
| Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study. | NCT03163381 | Osteosarcoma, A... | Apatinib | 18 Years - 70 Years | Henan Cancer Hospital | |
| Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer | NCT03377842 | Colorectal Canc... Neoadjuvant The... | FOLFOX regimen apatinib and FO... | 18 Years - | Sichuan Provincial People's Hospital | |
| Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors | NCT03660761 | Efficacy and Sa... | apatinib temodar | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. | NCT03384511 | Malignancies Stomach Cancer Non-small Cell ... Esophageal Canc... Breast Cancer Ovary Cancer Cervical Cancer | Apatinib | 18 Years - | Shandong Cancer Hospital and Institute | |
| The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus | NCT03520257 | Hepatocellular ... | Apatinib Radiotherapy | 18 Years - | Guangxi Medical University | |
| Study of Apatinib as an Inhibitor of Tumor Angiogenesis | NCT00633490 | Tumor | apatinib | 18 Years - 70 Years | Fudan University | |
| A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers | NCT03096184 | Head and Neck S... | Apatinib Mesyla... Tegafur Gimerac... | 18 Years - 70 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer | NCT03587129 | Ovarian Cancer | Apatinib | 18 Years - | First Affiliated Hospital of Harbin Medical University | |
| Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial | NCT03104335 | Soft Tissue Sar... Advanced Cancer | Apatinib | 16 Years - | Peking University People's Hospital | |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | NCT06346392 | Gastric Cancer Gastroesophagea... | AZD0901 AZD0901 Ramucirumab+ pa... Paclitaxel Docetaxel Irinotecan TAS-102 Apatinib | 18 Years - 130 Years | AstraZeneca | |
| Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | NCT03274011 | Esophageal Neop... | Apatinib | 18 Years - | Fudan University | |
| Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC) | NCT03046979 | Hepatocellular ... | Apatinib | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Apatinib for Resectable Colorectal Cancer | NCT03228043 | Apatinib Outcome, Fatal Colorectal Canc... Surgery Adjuvant Chemot... | Apatinib CAPEOX | 18 Years - 75 Years | Nanchong Central Hospital | |
| A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer | NCT03199677 | Refractory Canc... | Apatinib | 18 Years - 75 Years | ChineseAMS | |
| A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma | NCT03071042 | Metastatic Gast... | Apatinib Docetaxel | 18 Years - | Sir Run Run Shaw Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
